NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moonlake-loss-submission-form/?id=179740&from=3 CLASS PERIOD: March 10 ...

Core Insights - The lawsuit against MoonLake Immunotherapeutics, Inc. alleges that the company concealed material adverse facts regarding the clinical performance of its drug SLK, particularly in comparison to competitors like BIMZELX [2][3] - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these alleged misrepresentations [3] Legal Allegations - The lawsuit focuses on the alleged failure of MoonLake to disclose that SLK shares the same molecular targets as BIMZELX, which could mislead investors about its competitive positioning [3] - It is claimed that MoonLake misrepresented the efficacy of its Nanobody structure, suggesting it would provide superior clinical outcomes for treating hidradenitis suppurativa [3] - The legal focus includes whether investors are entitled to damages due to the alleged wrongful acts and omissions during the class period [3] Investor Actions - Investors who purchased MLTX shares between March 10, 2024, and September 29, 2025, and suffered losses are encouraged to contact Hagens Berman for potential legal action [4] - The deadline for investors to move the court for appointment as lead plaintiff is December 15, 2025 [1][5] Firm Background - Hagens Berman has a strong track record, having secured over $2.9 billion in settlements for investors in similar cases [4][6] - The firm specializes in corporate accountability and represents various stakeholders, including investors and whistleblowers [6]

PHILADELPHIA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the “Class Period”). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plainti ...

MLTX CLASS NOTICE: MoonLake Immunotherapeutics Securities Class Action Lawsuit is Pending, Investors Notified to Contact BFA Law by December 15December 08, 2025 8:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 8, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal se ...

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 15, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 2: Case Allegations - The complaint alleges that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, specifically concerning its molecular targets and clinical benefits [5]. - The lawsuit claims that when the true information was revealed, investors suffered damages due to the misleading nature of the defendants' statements [5].

Core Points - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the lead plaintiff deadline on December 15, 2025 for a class action lawsuit [1] - Investors who purchased shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the differences between Nanobodies and monoclonal antibodies, specifically about SLK and BIMZELX [5] - Key misleading claims include that SLK and BIMZELX share the same molecular targets, that SLK's Nanobody structure would not provide superior clinical benefits, and that its supposed tissue penetration would not lead to clinical efficacy [5] Legal Process - To join the class action, investors can visit the provided link or contact Phillip Kim, Esq. for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab, which led to a significant drop in stock price [1][2][6]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab compared to competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 to seek legal counsel before the December 15, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3][6]. - The lawsuit claims that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company concealed material adverse facts regarding its clinical performance and misrepresented the efficacy of its product SLK compared to competitors [2][3]. Legal Allegations - The lawsuit focuses on the alleged discrepancy between MoonLake's public statements and the actual clinical data from the Phase 3 VELA trials [3]. - It is claimed that MoonLake did not disclose that SLK shares the same molecular targets as BIMZELX, a competitor, which could mislead investors about SLK's competitive positioning [3]. - The company allegedly misrepresented that the Nanobody structure would lead to superior clinical efficacy, which was not supported by the trial results [3]. Financial Impact - MoonLake's stock price plummeted from $61.99 to $6.24, representing a 90% loss on September 29, 2025, following the disclosure of the alleged trial flaws [3]. - Investors who purchased shares during the Class Period (March 10, 2024, through September 29, 2025) and suffered losses are encouraged to contact the law firm for potential legal action [4]. Next Steps for Investors - The deadline for investors to move the Court for appointment as lead plaintiff is December 15, 2025 [1][5]. - Hagens Berman has a history of securing over $2.9 billion in settlements for investors, indicating a strong track record in similar cases [4][7].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, with a deadline for investors to join the case by December 15, 2025 [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [4]. Allegations and Clinical Data - The lawsuit claims that MoonLake misrepresented its clinical data, asserting that SLK's Nanobody structure provided superior clinical benefits compared to competitors, which was allegedly not true [5][6]. - The company claimed strong clinical data from its Phase 2 MIRA trial, suggesting higher clinical responses and differentiation from competitors [5]. Stock Performance and Impact - Following the disappointing results from the VELA Phase 3 trials reported on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].